Chromatin coregulators are important players in tumorigenesis and cancer progression. ANCCA is an AAA+ ATPase-containing nuclear coactivator for the estrogen and androgen receptors that is crucial for assembly of chromatin modifying complexes and proliferation of hormone-responsive cancer cells. In this study, we show that ANCCA is overexpressed in > 70% of breast tumors and that its high protein level correlates well with tumor histologic grades (P < 0.0001), highlighting ANCCA as a prognostic factor for poor overall survival and disease recurrence. Strikingly, high level ANCCA correlated with triple-negative tumors that represent highly aggressive disease. Analysis of ANCCA transcript levels in multiple expression profiles of breast cancer identified ANCCA as a common signature gene, indicating that elevated transcripts also strongly correlate with tumor metastasis and poor survival. Biological and mechanistic investigations revealed that ANCCA is crucial for proliferation and survival of triple negative/basal-like cancer cells and that it controls expression of B-Myb, histone methyltransferase EZH2
Introduction
Functional genomics and gene profiling studies of breast cancer continue to improve our prediction of clinical outcome and selection of therapeutics as well as our understanding of tumor biology, by subtyping the tumors on their molecular profiles. Among the subtypes, the luminal/estrogen receptorα positive (ER+) tumors present themselves as more differentiated, less aggressive, and highly responsive to endocrine therapy. Tumors overexpressing human epidermal growth factor receptor 2 (HER2), although often more aggressive, are responsive to therapeutics targeting the growth factor receptors. The triplenegative (ER, progesterone receptor, and HER2-negative) breast cancers or TNBCs, however, remain a major challenge for the development of effective therapeutics and identification of risk factors (1) . Recent expression array studies (2, 3) characterize most TNBCs as being basal-like due to an expression profile containing high levels of basal cell cytokeratins, similar to those of myoepithelial cells. Although poorly understood, one striking feature of TNBCs is the high expression of proliferation signature genes. Unlike ER-positive or HER2-high subtypes, no molecular markers have been defined that underpin TNBC development or effectively guide their clinical treatment. As a result, conventional chemotherapy remains the mainstay for them. Therefore, there is an urgent need for the identification of risk factors and new treatment options for triple negative tumors.
Chromatin coregulators, particularly in the forms of histone modifying and chromatin remodeling enzymes, have recently emerged as important players in tumorigenesis (4) (5) (6) . We recently identified a previously uncharacterized gene product dubbed ANCCA (for AAA+ nuclear coregulator cancer associated) as both a direct target and an activator of the proto-oncogene AIB1 (also known as ACTR and SRC-3) (7, 8) . ANCCA, a novel member of the AAA+ ATPase proteins, also possesses a bromodomain. cells per well of a six-well plate and maintained in full growth medium for 24 hrs before being infected with equal titers of adeno-ANCCA-HA or adeno-vector adenoviruses (8) . MDA-MB 468 cells were plated at a density of 2.0 x 10 5 cells per well in six well plates, and were transfected with siRNA 24 hours later as described above. Medium was changed every other day after transfection and cell proliferation was measured by cell counting of coded samples in triplicates. For colony formation in soft agar, five thousand cells were seeded in each well of six-well plates in medium containing 0.4% SeaPlaque® Agarose (Lonza) on top of base medium containing 0.8% agarose. Colonies were stained 4 to 5 weeks later with MTT (Sigma Aldrich) and counted using a light microscope. TUNEL assay. Cells were plated and transfected with siRNA 24 hours later as described above. Cells were plated 72 hrs later on glass chamber slides (Nunc) and processed for TUNEL assay using the In Situ Cell Death Detection kit (Roche Diagnostics) according to manufacturer's protocol. Slides were mounted with VECTASHIELD Mounting Media (Vector Laboratories). Images were acquired using Olympus BX6. For quantification of TUNEL-positive cells, 10 random fields of the same condition were counted and averaged. C for 2 hrs and processed for immunostaining. TMA for EZH2 and ANCCA correlation study has been described (7). Nonspecific immunoglobulin binding was blocked using 10% fetal bovine serum in PBS for 30 min at room temperature. Slides were then incubated at room temperature for 30 min with anti-ANCCA antibody (at 1:300), anti-Ki-67 (NeoMarker, at 1:300), and anti-EZH2 (AC22, Cell Signaling, at 1:50). Anti-ANCCA antibody was raised in rabbit (Covance) and affinity-purified by using GST-ANCCA N-terminus (aa 2-264) expressed and purified from E. coli. Its specificity for IHC was determined using a panel of cell lines and xenograft tumors (9) and is also shown in Supplementary Fig. 1 . After incubation with primary antibody, the sections were washed and incubated with biotin-conjugated secondary antibodies for 30 min followed by incubation with avidin DHbiotinylated horseradish peroxidase and developed using diaminobenzidine (DAB) substrate kit (Vector Laboratories) and counterstained using Gill's Hematoxylin. Images were acquired using an Olympus microscope with DPController software. The percentage of positively stained nuclei was scored as follows: 0-10%, score 0; 11-25%, score 1; 26-50%, score 2; >50%, score 3. The immunoreactivity was evaluated by at least two different investigators with no prior knowledge of patient data.
Statistical analyses and analysis of microarray gene expression data sets. Values of patient age and tumor size are presented as mean ± SE. Association between ANCCA immunoreactivity and other clinico-pathological parameters was evaluated using Pearson χ 2 test. Survival curves were generated using the Kaplan-Meier method taking into account censored data. The curves were compared using the log-rank test (Mantel-Cox). For other assays and analysis of gene transcripts in tumor data sets using its overexpression is associated with triple-negative status
To investigate ANCCA expression in breast cancer, we first performed immunohistochemical (IHC) analysis of ANCCA protein expression in a cohort of 225 primary human breast ductal carcinomas and three independent sets of TMAs containing a total of 131 tumor samples and 24 normal breast tissues.
Immuno-reactivity for ANCCA was readily detected in the nuclei of a large subset of tumor tissues while little or no staining was observed in the normal breast tissues or tumor-adjacent stroma ( Fig. 1 and Supplementary Fig. 2 ). When compared to normal breast tissue, over 70 % of all tumor samples examined showed increased levels of ANCCA protein expression (Table 1 and Supplementary Table 2 ).
Interestingly, although a large proportion (63%) of ERα-positive tumors displayed ANCCA overexpression, a much stronger association for its overexpression in ERα-and PR-negative tumors was observed (Table 1 ). More importantly, high levels of ANCCA associate significantly (P = 0.0071) with ERα-, PR-and HER2-negative status, as over 88% of all triple-negative samples showed high expression of ANCCA protein. Moreover, compared to normal human breast epithelial cells (HMECs), elevated levels of ANCCA proteins (~170 kD) was observed in all of the breast cancer cell lines examined ( Fig. 2A and Supplementary Fig. 1 ). Table 3) .
Consistent with our IHC analysis, ANCCA transcript examined in multiple studies displayed much higher levels in tumors than normal breast tissues ( Supplementary Fig. 3 ), and its high transcript levels strongly associated with ER-negative or triple negative status (P < 0.009 and P <0.0001 respectively, Supplementary Table 4) .
ANCCA overexpression correlates with tumor cell proliferation and disease progression
We next assessed the association of ANCCA expression with other clinical and pathological variables (Table 1) . Although no clear association was found between ANCCA level and lymph node status, we observed that high levels of ANCCA expression correlate strongly with higher histologic grades (P < 0.0001). Overall, more differentiated, low-grade tumors showed little to moderate expression of ANCCA, while less differentiated, high-grade tumors had markedly elevated levels of ANCCA protein ( We also examined whether strong ANCCA expression is predictive of disease progression by analysis of a cohort of 185 patients with up to 11 years of follow-up information. Tumors were divided into two groups (low ANCCA and high ANCCA) according to ANCCA IHC scores. As shown in Fig. 3A , patients whose tumors showed high ANCCA expression revealed a significantly shorter overall survival period when compared to those with no or weak ANCCA expression (P = 0.006 by Cox-Mantel log rank test; 80% survival for high ANCCA group, 2.5 years, and for low ANCCA, 5 years). When the relationship between ANCCA levels and survival was assessed with ER status taken into consideration, their association with poor survival can still be observed in patients with ER-negative tumors (P = 0.035, Supplementary Fig. 5 ).
Likewise, patients with high levels of ANCCA protein had an earlier time to disease recurrence compared to patients with low ANCCA expression (Fig. 3B) . Moreover, examination of ANCCA transcripts in the datasets of several "gene signature" studies revealed that high ANCCA mRNA levels associate with high probability of death and tumor metastasis (Fig 3C) .
ANCCA overexpression promotes anchorage-dependent and-independent proliferation and survival of TNBC cells
Since expression of ANCCA was particularly high in triple-negative tumors, we examined the role of overexpressed ANCCA in TNBC cells. As shown in Fig. 2A , ANCCA is highly overexpressed in the breast cancer cell lines relative to HMECs. Knockdown of ANCCA via one siRNA in MDA-MB-468 ( Fig   4A) , -231 (Fig 4C) , and -453 ( Supplementary Fig 6) cells showed strong inhibitory effects on their proliferation either in regular 2D culture or in a soft-agar, anchorage-independent growth assay.
Knockdown of ANCCA using a different siRNA gave a similar effect ( Supplementary Fig 7A and 7B ). In 
ANCCA controls important regulators of cell proliferation and survival pathways including EZH2 and B-Myb
Given the transcriptional coactivator function of ANCCA demonstrated in our previous study (7-9), we analyzed the TRANSBIG Consortium gene expression data set (12) , in which ANCCA serves as a prognostic signature gene, for genes having aberrant co-expression associated with overexpressed ANCCA. Strikingly, the analysis identified a group of genes highly enriched in control of cell proliferation and survival with the top 20 genes (25 gene probes) functioning primarily in mitosis (DLGAP5, BUB1, CEP55, KIF4A, KIF11, KIF15, KIF23, DSCC1, ECT2, SMC2, SMC4, GPSM2), DNA replication (MCM10 and Top2A) and cell cycle progression (Fig. 5A , and Supplementary Fig. 9 ).
Intriguingly, consistent with our IHC study, hierarchical clustering demonstrated that high levels of the gene transcripts including ANCCA cluster primarily in ER-negative tumors ( Despite our initial identification of ANCCA as a hormone-induced gene (8, 9) , we demonstrate here that high levels of ANCCA protein associate most strongly with TNBCs. We also show that high transcript levels of ANCCA tend to associate with ERα-negative or triple-negative status in several data sets from studies of multiple cohorts of tumors (19, 26, 35) . Moreover, our unbiased analysis of tumor gene expression datasets points to the association of high levels of ANCCA with the overexpression of other 16 (14) 25 (35) 17 ( 16 (14) 25 (35) 17 ( 
